Pediatric Hematology/Oncology, Children's Hospital, Hannover Medical School, Hannover, Germany.
Department of Pediatrics, Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama.
Pediatr Blood Cancer. 2018 Sep;65(9):e27089. doi: 10.1002/pbc.27089. Epub 2018 Apr 18.
The incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50-60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic benefit for AYA with AML enrolled in pediatric compared with adult trials is minor and only seen when different protocols are used. The distinctive needs of AYA, including intensive psychological services, call for their treatment within specialized centers that offer complex supportive care.
急性髓系白血病(AML)的发病率随年龄逐渐增加。有利的基因突变在儿童中最为常见,而不利的表型在青少年和年轻成人(AYA)中以及在成年后期呈比例增加。近年来,AYA 的生存率已提高到 50-60%,但其参与临床试验的比例仍然较低。与急性淋巴细胞白血病的 AYA 不同,在儿科与成人试验中入组的 AML 的 AYA 的预后获益较小,仅在使用不同方案时才可见到。AYA 的特殊需求,包括强化心理服务,需要在提供复杂支持性护理的专门中心进行治疗。